Highlights

  • OncoSil Medical completed its US Humanitarian Device Exemption application on 2 July 2026 for distal cholangiocarcinoma.
  • The company reported progress in manufacturing validation activities at its Sydney facility.
  • OncoSil continued international commercial activities with treatment centres operating across several markets.
  • The company held A$9.3 million in cash at 31 March 2026.
  • Future progress depends on regulatory outcomes, manufacturing readiness and commercial execution.

OncoSil Medical Progresses US Regulatory Pathway

OncoSil Medical Ltd (ASX: OSL) is advancing regulatory and commercial activities for its OncoSil device, a targeted internal radiotherapy treatment designed to deliver radiation directly into tumours.

The company recently completed its first United States regulatory submission through the Humanitarian Device Exemption (HDE) pathway. The application relates to distal cholangiocarcinoma, a type of bile duct cancer, rather than pancreatic cancer, which has been the focus of the company’s existing European activities.

On 2 July 2026, OncoSil confirmed that the final components of its HDE application had been submitted to the US Food and Drug Administration (FDA). The company stated that the FDA indicated an intention to complete the review within approximately 45 days.

The HDE pathway is designed for medical devices targeting rare conditions and involves specific regulatory requirements compared with other approval pathways.

Manufacturing Validation Activities Continue

Alongside regulatory progress, OncoSil is continuing manufacturing validation work at its Sydney facility operated with Cyclotek.

The company reported that three validation cycles had been completed, producing more than 50 doses. The validation program is supported by a A$2.1 million investment and remains targeted for completion in the first half of FY27.

Manufacturing capability is an important part of the company’s commercial plans, as regulatory approvals require the ability to produce consistent device batches.

OncoSil has indicated that the Sydney facility could support future commercial production, although routine commercial manufacturing has not yet commenced.

Clinical and Commercial Development Updates

OncoSil continues to evaluate the use of its device across cancer treatment applications.

The company released results from the TRIPP-FFX study presented at ESMO GI 2026. The study evaluated OncoSil combined with chemotherapy compared with chemotherapy alone in patients with unresectable locally advanced pancreatic cancer.

The company reported that median overall survival was 21.3 months in the combination group compared with 15.6 months in the chemotherapy-only group. The company also reported that the safety endpoint was achieved.

OncoSil stated that a regulatory change notification is planned for European and UK regulators later in 2026 regarding the pancreatic cancer indication.

Commercially, the company reported treatment activity across several European markets. The July 2026 presentation identified active implanting centres in Spain, Italy, Turkiye and Germany.

The device also received approval in Saudi Arabia during July 2026.

Financial Position and Funding Activities

OncoSil reported revenue of A$1.17 million for FY25, with a loss after tax of A$15.1 million. Operating cash outflow for the year was A$12.06 million, and cash at 30 June 2025 was A$5.11 million.

The company’s financial position has been supported through equity funding activities. During FY25, OncoSil raised approximately A$14.4 million before costs through several share issues.

A further capital raising increased cash holdings to A$9.3 million at 31 March 2026.

The company completed a 1-for-400 share consolidation on 29 May 2025, which reduced the number of shares on issue.

Understanding OncoSil’s Technology

The OncoSil device uses phosphorus-32 microparticles that are injected directly into a tumour under image guidance. The approach aims to deliver radiation internally within the tumour.

The company’s commercial strategy involves expanding use of the device across different cancer indications while developing regulatory approvals in additional regions.

The US HDE application represents an initial regulatory step in the United States market. However, the pathway is limited to specific rare conditions and does not represent approval across all potential uses.

Key Factors to Monitor

Future developments for OncoSil will depend on regulatory decisions, manufacturing progress and commercial adoption.

Key areas to monitor include the FDA decision on the HDE application, completion of manufacturing validation activities and progress with European regulatory submissions.

The company’s financial position and operating cash requirements will also remain important as it continues clinical and commercial activities.

Risks and Challenges

Regulatory outcomes remain a key uncertainty for OncoSil. While the company has submitted its HDE application, approval timing and final regulatory decisions remain outside the company’s control.

Manufacturing execution is another important factor, as commercial supply requires completion of validation activities and ongoing production capability.

The company also continues to manage funding requirements while expanding commercial operations and supporting development activities.

Conclusion

OncoSil Medical is progressing regulatory, manufacturing and commercial initiatives as it works to expand the use of its targeted radiotherapy device.

The completion of the FDA Humanitarian Device Exemption application represents a further step in its regulatory pathway, while manufacturing validation and international treatment activity continue to develop.

Future progress will depend on regulatory outcomes, manufacturing readiness and the company’s ability to expand commercial adoption across approved markets.